Skip to content
Open access

Successful application of сytokinetic therapy in the treatment of disseminated breast cancer (case report)

Oct 2026 · Lechaschi Vrach · 0 citations

Abstract

Background. Luminal B breast cancer is characterized by a worse prognosis and a higher risk of recurrence compared to luminal A. Unlike subtype A, it has a higher mutational load and PD-L1 expression, making it potentially sensitive to immunotherapy, including cytokine therapy. Objective. To evaluate the efficacy and safety of cytokine therapy as part of the antitumor treatment of disseminated luminal B breast cancer. Materiala and methods. A 46-year-old female patient with luminal B breast cancer (initially cT4N2M0) received combination therapy and hormonal therapy until August 2025. However, since August, progression with metastases to the bones, lymph nodes, lungs, pleura, and brain has been recorded. A biopsy confirmed invasive ductal carcinoma G2, ER 8 points, PR 7 points, Ki67 35%, HER2 0, wt BRCA. Since September 2025, monotherapy with paclitaxel has been prescribed, supplemented with radiation therapy to the brain and denosumab. A repeat contrast-enhanced computed tomography (CT) scan in January 2026 revealed growth of pulmonary lesions and lymph nodes (up to 15 mm), and a CA15-3 level of 633.5 U/ml. Therefore, by decision of the oncology council at the patient's place of residence, therapy was changed to capecitabine. Given the negative dynamics and deterioration of the patient's condition, the patient voluntarily presented to the clinic to supplement chemotherapy with cytokininogenetic therapy (CGT). During treatment, Karnofsky performance status, TNF-α and CA15-3 levels, and tumor progression using contrast-enhanced CT were monitored. Results. With cytokine gene therapy (CGT), significant improvements in well-being were noted after just three courses: weakness, shortness of breath, and pain decreased, and Karnofsky performance status increased from 60% to 87% by the sixth course. Contrast-enhanced CT showed stabilization of the tumor in the lung tissue and lesions in the mediastinal lymph nodes, and the sum of the largest and smallest diameters of the lesions decreased from 57 to 41 mm (a 28% reduction). CA15-3 tumor marker levels decreased by 4.1 times. The patient tolerated cytokine gene therapy well, with no drug toxicity observed. Overall survival since the start of CGT was 8+ months. Conclusion. This clinical case demonstrates the potential efficacy of a triple regimen (capecitabine + interferon-gamma + rFNT α1) in a patient with advanced luminal B breast cancer. However, randomized clinical trials are needed to definitively confirm its role in the treatment of such patients.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.